666 Views
Concurrent Session
World GI
O-013: Impact of gender on the safety profile and outcome of chemotherapy plus bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies
Gemma Zucchelli, et al
O-014: Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer (mCRC). A Danish randomized trial
Per Pfeiffer, et al
O-015: Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results
Per Pfeiffer, et al